companies developing glp-1 drugs Market Size to Hit USD 132.79 Bn by 2035 Novo cuts GLP-1 prices 70%,

Non-alcoholic fatty liver disease (NAFLD) is a common condition characterised by excessive fat accumulation in the liver of individuals who consume little to no alcohol (typically defined as less than 14 units per week in the UK)

So it's not just appetite control, it's actually beneficial throughout the body, and that we didn't see that one coming

We knew GLP-1s were not for everyone and the shortages across the industry made GLP-1s too expensive and too challenging to physically access

Healthcare providers administer liraglutide injection using an injector pen, and patients use it along with diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus

Binding of GLP-1 has been reported in the nucleus of the solitary tract (NTS) of the medulla oblongata as well

doi: 10.1038/s41386-019-0531-4 [DOI] [PMC free article] [PubMed] [Google Scholar] 165.Lau D, Gamble JM